Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced the start of the Phase IIb study with IPL512,602 in patients suffering from moderate to severe asthma. The study known as the Control of Asthma Patients Symptomatic on Inhaled Corticosteroids Study (CAPSICS), is an eight week, randomized, double blind, parallel group, multi-center trial comparing the efficacy of IPL512,602 to placebo.
